PUT/VERTEX PHARMACEUTICALS/350/0.1/17.01.25 | Real-time BOERSE MUENCHEN 05:56:44 18/06/2024 pm IST | ||
| 0.338 EUR | +1.50% |
|
| Current month | -47.14% | ||
| 1 month | -45.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 18/24/18 | 0.338 | +1.50% |
| 17/24/17 | 0.333 | +3.74% |
| 14/24/14 | 0.321 | -6.14% |
| 13/24/13 | 0.342 | +4.91% |
| 12/24/12 | 0.326 | -3.26% |
Real-time BOERSE MUENCHEN
Last update June 18, 2024 at 05:56 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GQ7533 |
| ISIN | DE000GQ75333 |
| Date issued | 09/10/2023 |
| Strike | 350 $ |
| Maturity | 17/01/2025 (213 Days) |
| Parity | 10 : 1 |
| Emission price | 2.79 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.64 € |
|---|---|
| Lowest since issue | 0.254 € |
| Spread | 0.3 € |
| Spread % | 46.88% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.7
USD
Average target price
463.4
USD
Spread / Average Target
-2.17%
- Stock Market
- Warrants
- Warrant
